Document:

International Assignment Agreement between Cisco Systems, Inc. & Wim Elfrink

 EXHIBIT 10.5 
 [CISCO LETTERHEAD] 
 November 19, 2007 
 Wim Elfrink 
 [ADDRESS] 
  

	Re:	International Assignment Agreement 

 Dear Wim: 

I am pleased to confirm your international assignment to India. This letter of agreement outlines the terms and conditions of your international assignment. Your
international assignment is also subject to the terms of Cisco’s Long Term International Assignment Policy (the “International Assignment Policy”) and the Tax Equalization Policy as they apply to international assignees
generally. However, where an express term of this Agreement and the International Assignment Policy conflict, this Agreement will govern. 
 Your point of
origin is the Netherlands (the “home country”) and your country of reference during your assignment is India (the “host country”). We understand you are a resident of the United States for tax purposes. 
 This Agreement supersedes and replaces, in its entirety, your previous Agreement of International Assignment from the Netherlands to the United States dated
November 9, 2001 and any prior employment agreement except to the extent set forth in Exhibit A or as otherwise required by the laws of the Netherlands. 
 New Assignment 
 Your international assignment began on January 3, 2007. 
 Effective as of August 13, 2007, your job title is Executive Vice President, Customer Advocacy and Chief Globalization Officer. In this capacity, you will report to John Chambers, or his successor(s) and/or
designee(s). As the Executive Vice President, Customer Advocacy and Chief Globalization Officer, you will be responsible for such duties and responsibilities as Mr. Chambers or his successor or designee assign. You will be required to travel in
India, and/or internationally during your international assignment. 

 Wim Elfrink 
 November 19,
2007 
 Page 2 
 Term 
 Although neither this assignment nor this letter alters your status as an at-will employee, it is anticipated that your international assignment will last for up to two
to three years. Your international assignment may be extended or shortened if expressly agreed upon in writing by you and Cisco. 
 Salary and Bonus 

 You will remain an employee of the home country and be paid on its payroll. Your annual base salary will be EUR 547,275 (USD 750,000 as of August 1,
2007). You will also be eligible to participate in Cisco’s Executive Incentive Plan (“EIP”). Your participation in the EIP will be subject to the terms and conditions of the EIP. Your target bonus percentage under the EIP for fiscal
year 2008 will be 125 percent (125%) of your annual base salary. 
 Your salary and bonuses will be paid to you in Euro from your home country less
applicable deductions and withholdings; however, pursuant to the Tax Equalization Policy, you will receive a Host Country Tax Payment to off-set any additional amounts you are required to pay in taxes due to your international assignment on the same
basis as other international assignees. 
 Benefits 
 Life
insurance, business travel accident insurance, retirement plans, disability and healthcare coverage will be provided from the home country while on assignment. For additional information about benefits coverage, please refer to the Benefits section
on Cisco’s intranet and access the link to Worldwide Plans. Your vacation entitlements will continue to be governed by the policies in effect for the home country and your PTO accrual will remain unchanged. However, working hours, public
holidays and sick leave will follow policies in effect for the host country, India. 
 Please be aware that in the case of a medical or security emergency,
Cisco has contracted with International SOS (“ISOS”) to provide employees working abroad with access to a full range of medical information and emergency services, including medical assistance, international healthcare, security services
and outsourced customer care. Additional information about ISOS, is available on Cisco’s intranet at wwwin.cisco.com/employee/benefits/isos.shtml. 
 Relocation 
 [                    ] of Cartus has been working with the ART Group (“ART”) and Fragomen, Del Rey, Bernsen &
Loewy, LLP (“Fragomen”) to arrange all aspects of your international relocation. To the extent that your relocation is not already completed,
[                    ], together with ART and Fragomen will continue to assist you with various details and arrangements, including: passport,
visa, and local work permit requirements; housing requirements; transportation to your new location; and shipment of household goods and personal effects. 

 Wim Elfrink 
 November 19,
2007 
 Page 3 
 Cisco has provided relocation assistance to
India for you, your spouse and your children, and covered many of the expenses associated with the move. Cisco will continue to provide relocation assistance to India for you, your spouse and your two sons, and cover the following expenses:

  

	 	•	 	 You and your family will receive a host country cultural orientation and language training to assist with your move. 

 On-Going Allowances and Reimbursements 
 Cisco has adopted a
“Balance Sheet Approach” in compensating employees on international assignments, to ensure that assignees can maintain purchasing power similar to that which they would have enjoyed in their home country, assuming the same salary, grade
level and family size. Therefore, during your international assignment, you will be entitled to the following allowances or reimbursements to cover additional costs incurred as a result of your international assignment. In addition, any amount of
allowance/reimbursement that is not used by you in any given month shall be carried over to the next month(s) and made available to you (in addition to the maximum allowance specified) in the subsequent month(s). Notwithstanding the foregoing, with
respect to any allowance/reimbursement that would otherwise be treated as a deferred compensation arrangement under Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) if the amount were carried over into a
subsequent taxable year, any portion of such allowance/reimbursement that is unused as of each December 31 (including amounts carried over from a prior month in the same calendar year) shall not be carried-over into the next calendar year and
made available to you. Cisco will reimburse you for business expenses in accordance with Cisco’s applicable reimbursement policies; however, if you incur any business related travel expenses that are not reimbursed by Cisco under such policies,
any of the allowances below may be used to cover such expenses. 
 Housing Assistance: 
 Cisco will reimburse the monthly rental payments on the residence that will be leased on your behalf in India. You understand and agree that your host country residence will be used not only as your personal
residence, but for business purposes as well, including as a forum to showcase and test Cisco’s technology. The annual cost for this lease is not to exceed INR 24,632,200 (USD 556,932 as of January 3, 2007) with scheduled annual inflation
increases pursuant to the signed lease contract. 
 In order to maintain the property, Cisco has contracted with Epitome services for house maintenance to be
paid on your behalf by Cisco. The annual cost of this benefit is not to exceed INR 2,600,000 (USD 58,786 as of January 3, 2007). Cisco will also reimburse you for the cost of domestic household assistance. The annual cost of this benefit is not
to exceed INR 710,000 (USD 16,053 as of January 3, 2007). 

 Wim Elfrink 
 November 19,
2007 
 Page 4 
 For your security and the security of
Cisco’s property, Cisco has contracted with a security firm for these services to be paid on your behalf. The annual cost of this benefit is not to exceed INR 1,212,000 (USD 27,403 as of January 3, 2007). 
 Cisco will continue to provide housing assistance in the United States as it will be necessary for you to return to the United States for business purposes. This housing
assistance will be paid from the Netherlands payroll in the monthly amount not to exceed EUR 10,835 (USD 14,845 as of August 1, 2007). Cisco will continue to assist with the costs of utilities in the United States at a cost not to exceed USD
300 per month. 
 Property Management: 
 If you elect
not to sell or rent your home country residence, Cisco will reimburse you for the costs for property management of that residence in accordance with the International Assignment Policy. 
 Dependent Education Reimbursement: 
 Cisco will reimburse you the annual cost of tuition for each of your dependent
children attending elementary or secondary school at the host location with a cost not to exceed INR 1,000,000 (USD 22,610 as of January 3, 2007) in the aggregate per school year. 
 Home Leave Travel Allowance: 
 Cisco will reimburse you for the cost of airfare for you, your spouse, and your
children to return to your home in the Netherlands or to the United States each year. As a guideline, this allowance typically covers three trips per year. The annual cost of this benefit is not to exceed USD 50,000. 
 Automobile Assistance: 
 The costs for the rent or purchase two
family-style automobiles, the services of two drivers during your international assignment and standard automobile insurance on such two vehicles for you and your spouse will be paid on your behalf by Cisco. The annual cost is not to exceed INR
2,381,800 (USD 53,852 as of January 3, 2007). 
 In addition, Cisco will continue to pay you the transportation allowance that you were provided in
connection with your international assignment to the United States from the Netherlands as it will be necessary for you to return to the United States for business purposes. That allowance shall continue to be paid through payroll in the Netherlands
and shall be in the amount of EUR 1,850 (USD 2,535 as of August 1, 2007) each month. 
 Relocation Payment: 
 After you have completed your first full year working on international assignment in India, Cisco will pay you a lump sum relocation allowance equal to EUR 27,574 (USD
37,776 as of August 

 
Wim Elfrink 
 November 19, 2007 
 Page 5 
 1, 2007) per year paid through payroll in the Netherlands for
relocation, adjustment and transition assistance. The first payment shall be made on or about the one year anniversary of your international assignment and subsequent payments on or about your subsequent annual anniversary dates. This payment shall
be in lieu of the Miscellaneous Relocation Payment set forth in the International Assignment Policy. 
 The assignment allowances will have already been
implemented. Please notify [                    ] of Cartus, if you have any questions regarding these payments. In addition, please notify
Cartus of any changes in your family size within 30 days while you are on assignment. These changes may affect the structuring of your benefits package or allowances. 
 Repatriation 
 Upon completion of your international assignment, Cisco will provide you with relocation assistance
related to your move back to the United States. This will include one-way business class travel for you and your qualifying dependents; shipment of household goods and personal effects and temporary living in your home country. 
 Assuming your international assignment is successful, upon its termination Cisco will attempt to employ you in a position comparable to your then current position and
which utilizes the skills and experience you gained during your international assignment. If Cisco is unable to provide you with a position comparable to your then current position, Cisco will attempt to provide you with a position comparable to
your position immediately prior to the commencement of your international assignment. Your base salary and target bonuses, in either case, will be at a level commensurate with the position offered. If Cisco is unable to offer you a position, your
employment will terminate and Cisco will pay you an amount equal to the sum of (i) one year of your then current annual salary, and (ii) the target annual bonus for your level under the EIP (together the “Severance”).
Cisco’s obligation to pay the Severance will be contingent upon your execution and the effectiveness of a release agreement in a form provided by Cisco within 30 days of your “separation from service” from Cisco as that term is
defined in Section 409A. This Severance would be in lieu of any entitlement you may have to notice of termination, to pay in lieu of notice of termination, or to any other severance payment from any source. This section supersedes any
termination of employment provision of the International Assignment Policy. 
 Taxes 
 Your international assignment will be covered by Cisco’s Tax Equalization Policy and you hereby acknowledge that you have accepted all the terms and conditions set forth in Exhibit B. Your pay will be subject to
annual hypothetical tax deductions in amounts determined by Ernst & Young (“EY”). Cisco’s philosophy regarding tax equalization is that as an international assignee, you will neither materially gain nor lose from the
differences in income and social tax costs between your home and host country, within certain parameters. Tax equalization applies to Cisco equity awards as described in the Tax Equalization Policy. Any Indian Fringe Benefits tax related to your
equity income will be handled in the same manner as other international assignees assigned to India. For purposes of tax equalization, your home country will be the 

 Wim Elfrink 
 November 19,
2007 
 Page 6 
 United States. Cisco has retained EY, an
independent tax accounting firm, to provide assistance with the preparation of both your home and local country tax filing obligations and to prepare annual tax equalization calculations. Please contact
[                            ] in EY’s Tax Department for any questions. 
 Fees associated with tax services provided by EY and other tax consulting services, including any services provided by your tax advisor in the Netherlands, shall be paid
on your behalf by Cisco not to exceed USD 75,000 per year. 
 Notwithstanding the foregoing, if this Agreement or any benefit payable to you hereunder
is subject to Section 409A and you are a “specified employee” (within the meaning of Section 409A) as of the date you separate from service from Cisco, then any payments scheduled to be made to you pursuant to this Agreement
during the first six months following your separation from service shall be delayed and shall accrue interest at the applicable federal rate for such six month period. The delayed payments (and including any accrued interest) shall be paid
immediately following the end of the six month delay. In no event shall Cisco be liable for any taxes or penalties imposed under Section 409A with respect to any benefit(s) paid to you pursuant to this Agreement. All reimbursements under this
Agreement that are subject to Section 409A shall be made no later than the end of the calendar year next following the calendar year in which the applicable expenses are incurred and the Severance, if any, shall be paid no later than the 15th
day of the third month following the year in which your international assignment terminates. Any tax equalization payments shall be paid within the time periods described in Section 1.409A-1(b)(8)(iii) of the Treasury Regulations under
Section 409A. 
 Dispute Resolution 
 You and Cisco
acknowledge and agree that any and all disputes or claims arising from or relating to your recruitment to or employment with Cisco (including but not limited to disputes or claims arising from or relating to this Agreement), or the termination of
your employment, will be resolved solely and exclusively pursuant to final and binding arbitration in lieu of any evidentiary hearing before a government agency and/or a court trial before a judge or jury, pursuant to the terms of Cisco’s
Arbitration Agreement and Policy, a copy of which can be found at http://wwwin.cisco.com/HR/employee/proprietary_info/agreement2arbitrate.shtml. The agreement to arbitrate means that both you and Cisco have expressly waived any and all rights
to a trial before a court or a jury. 
 General 
 Cisco’s personnel policies and standards of business apply to your assignment, unless a written exception is provided by a company representative authorized to make that exception or is otherwise set forth in this Agreement.

 This Agreement sets forth the entire agreement between you and Cisco regarding your international assignment except that existing agreements with Cisco
such as your agreement to arbitrate, your proprietary information and inventions agreement and agreement(s) establishing at-will employment are not superseded by this agreement, unless expressly provided to the contrary herein. 

 Wim Elfrink 
 November 19,
2007 
 Page 7 
 This Agreement can only be modified by a written
document signed in writing by Randy Pond or his successor(s) or designee(s) and approved by the Compensation and Management Development Committee of the Board of Directors. Please note that Cisco reserves the right to unilaterally modify the
provisions of this Agreement and/or the documents incorporated herein as legal requirements may dictate, new practices may require or for other reasons at the discretion of Cisco. In the event such modifications are made, notification will be
provided to you. 
 This Agreement shall be governed by, and construed in accordance with, the laws of the State of California (except its choice-of-law
provisions). 
 We are excited to have you join our operations in India. If you are in agreement with the terms and conditions of your assignment as outlined
in this letter and in the attached policies, please sign the two originals and return one to the person listed below. 
  

											
	BY CISCO SYSTEMS, INC.	 		 		 	APPROVED & ACCEPTED	 	
	  
 /s/ Randy Pond
  
 Randy
Pond                            
	 	  
 November 19, 2007
 Date
	 		 	  
 /s/ Wim Elfrink
  
 Wim Elfrink                            
	 	  
 November 19, 2007
 Date

	 Executive Vice President, Operations,
 Processes and
Systems
	 		 		 	Executive Vice President, Customer Advocacy and Chief Globalization Officer	 	
				
	Return one original to:	 		 	[                    ]	 	
		 		 	Cisco Systems, Inc.	 	
		 		 	170 West Tasman Dr.	 	
		 		 	San Jose, CA 95134	 	
		 		 	United States	 	

 EXHIBIT A 
  

	1.	Termination of the Employee’s home country employment agreement will be subject to a notice period of two (2) months. Notice must be given before the end of a calendar
month, in which case the formal notice period will start on the first day of the month following the month during which notice was served. 

  

	2.	The Employee shall be entitled to an annual holiday allowance of 8% of the gross annual base salary, payable in the month of May of the current year. If the Employee performed work
during only a part of the year, the holiday allowance shall be calculated and paid proportionately. 

  

	3.	The Employee shall be entitled to 25 days’ holiday a year, which the Employee shall take in consultation with and after approval by the Employer. 

 In principle, accrued holidays must be taken in the calendar year in which they accrue. Excess holidays (i.e., holidays accrued during a certain year
which have not been taken during the calendar year in which they accrued) must be taken between 1 January and 1 April of the subsequent calendar year in consultation with the Employer. If, after consultation, the holidays are not taken
during the said period, the Employer shall designate the period during which the holidays must be taken. If, in spite of this, the designated holiday period is not taken, the claim to the excess holidays shall lapse. 
 Upon termination of the employment relationship, the Employee shall not be entitled to any salary over holidays and/or hours which have been taken but
which have not yet accrued. The Employee shall be obliged to repay the Employer any salary already received over such holidays and/or hours at the end of the employment relationship. 
  

	4.	If the Employee is ill or unable to perform work for any other reason, he shall be obliged to inform the Employer thereof on the first day of absence. 

 If the Employee is unable to perform his work as a result of illness, he shall remain entitled to 100% of his last earned salary for a period of 52 weeks,
unless the illness was caused intentionally by him or ensued from an infirmity in respect of which he intentionally gave the Employer false information when he entered into the employment agreement, in the event he causes an obstruction of or delay
in the recovery process, or if the Employee - despite being able to do so - refuses to perform other suitable work for his own Employer or - with the prior approval of the Industrial Insurance Board - for another employer. 
 The wages will be reduced by: 
 - the amount
of any financial benefit which the Employee receives under any statutorily prescribed insurance or under any insurance or from many fund which was agreed upon in or results from the employment agreement; 
 - the amount of income earned by the Employee, whether in or outside the employer-employee relationship, from work which he has performed in the period
during which the contractually agreed work could have been performed if he had not been prevented from doing so. 

 If the Employee’s incapacity for work was caused by a third party, the Employer shall not be obliged
to pay the Employee’s salary or a supplement to his social security benefits. If, in that case, the Employee can hold a third party liable for loss of income in connection with his incapacity for work, he shall assign his claim against the
third party to the Employer, for which he will receive an amount equal to the amount which he would have received if the third party had not been involved in the incapacity for work. The Employer will pay the amount to which the Employee is in that
case entitled in monthly installments, the amount of which shall be determined by the Employer. 
 The Employer will not invoke the provisions
contained above, if and insofar as the Employee cannot hold the third party liable. 
  

	5.	The Employer shall compensate 50% of the Employee’s premium payable for the standard insurance class of the Company’s health insurance plan. The Company does not
contribute to the costs of participating in insurance plans other than the Company plan. 

 The Employer has taken out accident
insurance, i.e. “Cisco’s Worldwide Business Travel Accident Insurance (BTA)”, for the benefit of the Employee. 
  

	6.	As required, the Employee has joined the employers pension scheme in the Netherlands. Both employee and employer participate in the costs of this scheme. Under the scheme there is
an employer contribution for the following pensions: old age pension, survivors pension, orphans pension and occupational disability benefit. By way of example, for fiscal 2007, Cisco’s contribution to this scheme was approximately EUR 135,000
(USD 184,950 as of August 1, 2007). The contribution percentage increases with age and the contribution amount is generally determined as a percentage of certain cash compensation of the employee. Contributions are used to purchase insurance
which has a specified minimum guaranteed annual rate of return. 

  

	7.	Neither during the employment term nor upon termination of the employment shall the Employee inform any third party in any form, directly or indirectly, of any particulars
concerning or related to the business conducted by the Employer or its affiliated companies which he could reasonably have known were not intended for third parties, regardless of the manner in which he learned of the particulars.

 Any violation of the obligation to maintain confidentiality as set forth in the preceding paragraph shall carry a penalty of
NLG 10,000, immediately payable by the Employee to the Employer and without prejudice to any other claims which the Employer may have, including the right to full damages. 
  

	8.	Insofar as the rights specified hereinafter are not vested in the Employer by operation of law on the grounds of the employment relation between the parties, the Employee covenants
that he shall transfer and, insofar as possible, hereby transfers to the Employer any rights of whatever nature in or arising from inventions made by the Employee in the discharge of his duties, both in the Netherlands and abroad.

  

	9.	The foregoing provisions on this Exhibit A shall be governed by the laws of the Netherlands. 

 EXHIBIT B 
 CISCO SYSTEMS, INC. 
 INTERNATIONAL ASSIGNMENT TAX EQUALIZATION POLICY AGREEMENT 
 I acknowledge having read the Tax Equalization Policy of Cisco Systems, Inc. (“Cisco”), located at
http://wwwin.cisco.com/FinAdm/Tax/StockOptions/stock_faq.shtml, and understand the personal impact of the Policy. Any questions concerning this Policy with Cisco have been fully explained to my satisfaction. I accept that all interpretations
under this agreement shall be controlled by the Policy of Cisco, which is included as part of this agreement. Cisco shall have the right and privilege at any time it deems necessary and proper to amend, add, or delete provisions to and from this
Policy without prior notice. 
 I understand and agree that all tax positions affecting income, deductions and credits outside the scope of the Policy (i.e.,
amounts not covered by the Policy) are the responsibility of the employee. Cisco is not liable for any taxes, penalties, or interest resulting from a successful challenge by any tax authority of any item not covered by the Policy. 
 In addition, I understand the employee is fully responsible for all penalties and interest charges assessed by any tax authority due to the employee’s failure to
(1) provide information to Ernst & Young on a timely basis, (2) notify Ernst & Young of any significant personal income or investment transactions, or (3) cooperate with Cisco with respect to the tax equalization
process. 
 I understand and agree that Cisco will reduce my compensation by an estimated hypothetical tax. The estimated hypothetical tax is an amount which
approximates my periodic estimated tax deductions calculated with reference to compensation, benefits, deductions and credits otherwise available to me had I remained in my home country, except as otherwise provided in this Policy. In return, Cisco
will advance wages that I have not yet earned to assist with the payment of my actual home and host country tax liabilities within the limits prescribed by the Policy. 
 I understand that these wage advances provided by Cisco for payment of taxes constitutes an obligation by me to Cisco, which will be reconciled with the final liabilities that are Cisco’s responsibility through
the annual tax equalization settlement calculation. After completion of the tax equalization settlement statement for each taxable year, I agree to repay any obligation for each taxable year within thirty (30) days. If I fail to repay any
obligation to Cisco within thirty (30) days after completion of the tax equalization settlement statement, then, unless Cisco and I have agreed otherwise in writing, Cisco shall have the right to: 
  

	 	a)	reduce any foreign assignment allowances or reimbursements due to me, and/or 

  

	 	b)	reduce future amounts paid to me whether as wages, salary or other compensation for services performed in light of my having received wage advances that I have not yet earned.

 The total obligation will become immediately due and payable if my employment with Cisco or any of its affiliate corporations is terminated,
whether voluntarily or involuntarily. 

 If I fail to furnish tax records in response to a request by Cisco pursuant to the Policy, or cease employment with Cisco
or any of its subsidiaries for any reason before the tax records needed to complete the year-end tax equalization settlement statement under the Policy are available, then Cisco shall have the right to calculate such amounts by making reasonable
assumptions of probable taxes. If an amount is owed to Cisco, Cisco shall also have the right to require immediate payment of such amount, including the right to reduce future amounts paid to me whether as wages, salary or other compensation for
services performed in light of my having received wage advances that I have not yet earned, unless Cisco and I have agreed otherwise in writing.Fifth Amended and Restated Investors' Rights Agreement dated July 12, 2006

 Exhibit 4.2 
 FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 This Fifth Amended and
Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of July 12, 2006 by and among Broncus Technologies, Inc., a California corporation (the “Company”), and the persons and
entities listed on Exhibit A attached hereto (the “Investors”). 
 WITNESSETH: 
 WHEREAS, certain of the Investors (the “Prior Investors”) are holders of outstanding shares of the Company’s Common Stock
(“Common Stock”), Series A-1 Preferred Stock (“Series A-1 Stock”), Series A-2 Preferred Stock (“Series A-2 Stock”), Series A-3 Preferred Stock (“Series A-3 Stock”), Series B
Preferred Stock (“Series B Stock”), Series C Preferred Stock (“Series C Stock”), Series D Preferred Stock (“Series D Stock”) and/or Series E Preferred Stock (“Series E Stock”),
which securities were issued by the Company to such Prior Investors at three closings pursuant to that certain Stock Purchase Agreement by and among the Company and certain of the Prior Investors dated as of February 7, 1997, at two closings
pursuant to that certain Series B Preferred Stock Purchase Agreement by and among the Company and certain of the Prior Investors dated as of July 14, 1998 and the Amendment thereto dated as of September 15, 1998, at one closing pursuant to
that certain Series C Preferred Stock Purchase Agreement by and among the Company and certain of the Prior Investors dated as of December 23, 1999, at one closing pursuant to that certain Series D Preferred Stock and Warrant Purchase Agreement
by and among the Company and certain of the Prior Investors dated as of February 13, 2002, and at four closings pursuant that certain Series E Preferred Stock Purchase agreement by and among the Company and certain of the Prior Investors dated
as of March 19, 2004, as amended September 10, 2004 (collectively, the “Prior Stock Purchase Agreements”) and/or are holders of a warrant to purchase shares of Series E Preferred Stock issued to Venture Lending &
Leasing III, LLC on April 8, 2004 (the “VLL Warrant”) or a warrant to purchase shares of Series E Preferred Stock issued to Angiotech Pharmaceuticals, Inc. on June 21, 2005 (the “Angiotech
Warrant”). The Prior Investors have also been granted certain information and registration rights and rights of first refusal under a Fourth Amended and Restated Investors’ Rights Agreement by and among the Company and the Prior
Investors dated as of March 19, 2004, as amended on September 10, 2004 and on June 21, 2005 (the “Prior Rights Agreement”); 
 WHEREAS, certain of the Investors (the “Series F Investors”) have agreed to purchase shares of the Company’s Series F Preferred Stock (“Series F Stock”) and to acquire
warrants to purchase Series F Stock (the “Series F Warrants”) pursuant to that certain Series F Preferred Stock Purchase Agreement by and among the Company and such Series F Investors dated of even date herewith (the
“Series F Agreement” and together with the Prior Stock Purchase Agreements, the “Stock Purchase Agreements”). The Series F Agreement provides that, as a condition to the Investors’ purchase of Series F Stock
thereunder, the Company will enter into this Agreement and the Investors will be granted the rights set forth herein; and 
 WHEREAS, the
Company and the undersigned parties hereto desire to enter into this Agreement in order to amend, restate and replace their rights and obligations under the Prior Rights Agreement with the rights and obligations set forth in this Agreement. 

 
Section 4.2 of the Prior Rights Agreement provides that the Prior Rights Agreement may be amended by the written consent of the holders of at least 2/3
of the “Investors’ Shares” (as defined in Section 4.2 of the Prior Rights Agreement) and the undersigned parties to this Agreement hold at least 2/3 of the Investors’ Shares, as defined in the Prior Rights Agreement.

 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants, and for other consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	INFORMATION RIGHTS. 

 1.1
Financial Information. The Company covenants and agrees that, commencing on the date of this Agreement, for so long as any Investor holds at least 750,000 shares of any combination of shares of Series A-1 Stock, Series A-2 Stock, Series
A-3 Stock, Series B Stock, Series C Stock, Series D Stock, Series E Stock or Series F Stock (the “Preferred Stock”) or Common Stock, or any combination thereof issued under the Stock Purchase Agreements and/or the equivalent number
(on an as-converted basis) of shares of Common Stock of the Company issued upon the conversion of such shares of the Preferred Stock (“Conversion Stock”) and/or shares of Common Stock issued or issuable upon exercise of the
Angiotech Warrant (each, a “Major Investor”), the Company will: 
 (a) Annual Reports. Furnish to such Major
Investor, as soon as practicable and in any event within ninety (90) days after the end of each fiscal year of the Company, a consolidated Balance Sheet as of the end of such fiscal year, a consolidated Statement of Income and a consolidated
Statement of Cash Flows of the Company and its subsidiaries for such year, setting forth in each case in comparative form the figures from the Company’s previous fiscal year (if any), all prepared in accordance with generally accepted
accounting principles and practices and audited by nationally recognized independent certified public accountants; 
 (b)
Quarterly Reports. Furnish to such Major Investor as soon as practicable, and in any case within forty-five (45) days after the end of each fiscal quarter of the Company (except the last quarter of the Company's fiscal year),
quarterly unaudited financial statements, including an unaudited Balance Sheet, an unaudited Statement of Income and an unaudited Statement of Cash Flows; 
 (c) Monthly Reports. Furnish to such Major Investor as soon as practicable, and in any case within twenty (20) days of the end of each calendar month (except the last month of the Company’s
fiscal year and the last month of each fiscal quarter), monthly unaudited financial statements, including an unaudited Balance Sheet, an unaudited Statement of Income and an unaudited Statement of Cash Flows, together with a comparison to the Annual
Plan (as defined below) and statements of the Chief Financial Officer of the Company explaining any significant differences in the statements from the Annual Plan for the month covered and stating that such statements fairly present the consolidated
financial position and consolidated financial results of the Company for the month covered; and 
  

 - 2 - 

 (d) Annual Budget. Furnish to such Major Investor as soon as practicable and in any event at
least thirty (30) days prior to the close of each fiscal year of the Company, an annual operating plan and budget, broken down by month and in reasonable detail, for the next immediate fiscal year (the “Annual Plan”). The
Company shall also furnish to such Major Investor, within a reasonable time of its preparation, amendments to the Annual Plan, if any. 
 (e) Confidentiality. Each Investor agrees to hold all information received pursuant to this Section 1 in confidence, and not to use or disclose any of such information to any third party, except to the extent such information
may be made publicly available by the Company and except as required by law; provided, however, that Investors may make such disclosures on a confidential basis as are reasonably necessary to their limited partners, affiliates, agents,
attorneys or accountants to monitor and protect their investment in the Company. 
 (f) Limitations on Disclosure. Notwithstanding
anything to the contrary in this subsection 1.1, the Company may exclude from any information otherwise required to be provided to the holder of the Angiotech Warrant (or the shares of stock issued upon any exercise thereof), any confidential
information which the Company reasonably believes is of a sensitive nature and should not be provided in light of such holder’s interests (other than its interests solely as a holder of the Company’s securities), provided that nothing
herein limits the Company’s obligations to provide information, or the holder of the Angiotech Warrant’s right to receive information, pursuant to agreements other than the Angiotech Warrant or this Agreement. 
 1.2 Inspection Rights. The Company hereby grants to each Major Investor, at such Investor’s expense, the right to visit and inspect any of
the properties of the Company or any of its subsidiaries, to examine its books of account and records and to discuss the Company’s and any of its subsidiaries’ affairs, finances and accounts with their respective officers, all at such
reasonable times as may be requested by such Investor for purposes solely of monitoring its investment in the Company. 
 1.3 Reservation
of Common Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 
 1.4 Termination of Certain Rights. The Company’s obligations under Sections 1.1 and 1.2 above will terminate upon the
closing of the Company’s initial public offering of Common Stock pursuant to an effective registration statement filed under the U.S. Securities Act of 1933, as amended (the “Securities Act”); provided,
however, that in the event that such initial public offering does not constitute a “Qualified Public Offering” (as defined in Section 3.5 below), then the obligations under Sections 1.1 and 1.2 above shall, in the event that
the Company is thereafter not required to file annual or periodic reports with the Securities and Exchange Commission under Section 13 or Section 15 of the Securities Exchange Act of 1934, as amended, be reinstated as to any Investor who
continues to hold shares of Preferred Stock and who holds the requisite number of shares of the Company’s Preferred Stock and/or Conversion Stock for so long as such Investor continues to hold any shares of Preferred Stock and such requisite
number of shares of Preferred Stock and/or Conversion Stock. 
  

 - 3 - 

	 	2.	REGISTRATION RIGHTS. 

 2.1
Definitions. For purposes of this Section 2: 
 (a) Registration. The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such
registration statement. 
 (b) Registrable Securities. The term “Registrable Securities” means:
(1) all the shares of Common Stock of the Company issued or issuable upon the conversion of any shares of Preferred Stock issued under any of the Stock Purchase Agreements, or issued or directly or indirectly issuable upon exercise of the
Angiotech Warrant, the VLL Warrant or the Series F Warrants (such warrants hereafter sometimes collectively referred to as, the “Warrants”) and (2) any shares of Common Stock of the Company issued as (or issuable upon the
conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, all such shares of Common Stock described in clause (1) of this
subsection (b); excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which rights under this Section 2 are not assigned in accordance with this Agreement or any Registrable Securities sold to
the public or sold pursuant to Rule 144 promulgated under the Securities Act. 
 (c)
Registrable Securities Then Outstanding. The number of shares of “Registrable Securities then outstanding” shall mean the number of shares of Common Stock which are Registrable Securities and
(1) are then issued and outstanding, or (2) are then issuable pursuant to the exercise or conversion of then outstanding and then exercisable options, warrants or convertible securities. 
 (d) Holder. For purposes of this Section 2 and Sections 3 and 4 hereof, the term “Holder” means any person owning of record
Registrable Securities that have not been sold to the public or pursuant to Rule 144 promulgated under the Securities Act or any assignee of record of such Registrable Securities to whom rights under this Section 2 have been duly assigned in
accordance with this Agreement; provided, however, that for purposes of this Agreement, a record holder of shares of Preferred Stock convertible into such Registrable Securities shall be deemed to be the Holder of such Registrable
Securities and a record holder of any of the Warrants directly or indirectly exercisable for such Registrable Securities shall be deemed to be the Holder of such Registrable Securities directly or indirectly issuable upon exercise thereof); and
provided, further, that the Company shall in no event be obligated to register shares of Preferred Stock or Warrants and that Holders of Registrable Securities will not be required to convert their shares of Preferred Stock into Common
Stock or to exercise their Warrants in order to exercise the registration rights granted hereunder, until immediately before the closing of the offering to which the registration relates. 
 (e) Form S-3. The term “Form S-3” means such form under the Securities Act as is in effect on the date hereof or any
successor registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
  

 - 4 - 

 (f) SEC. The term “SEC” or “Commission” means the U.S.
Securities and Exchange Commission. 
  

	 	2.2	Demand Registration. 

 (a)
Request by Holders. If the Company shall receive (i) at any time before the initial public offering of the Company’s stock registered under the Securities Act, a written request from the Holders of at least two-thirds of
the Registrable Securities then outstanding, or (ii) at any time after the initial public offering of the Company’s stock registered under the Securities Act a written request from the Holders of Registrable Securities that the Company
file a registration statement under the Securities Act covering the registration of Registrable Securities pursuant to this Section 2.2, then the Company shall, within ten (10) business days of the receipt of such written request, give
written notice of such request (“Request Notice”) to all Holders, and effect, as soon as practicable, the registration under the Securities Act of all Registrable Securities which Holders request to be registered and included
in such registration by written notice given by such Holders to the Company within twenty (20) days after receipt of the Request Notice, subject only to the limitations of this Section 2.2; provided, however, that the
Registrable Securities requested to be registered pursuant to (ii) above must have an anticipated aggregate public offering price (before any underwriting discounts and commissions) of not less than Seven Million Five Hundred Thousand Dollars
($7,500,000). 
 (b) Underwriting. If the Holders initiating the registration request under this Section 2.2
(“Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, then they shall so advise the Company as a part of their request made pursuant to this Section 2.2 and
the Company shall include such information in the written notice referred to in subsection 2.2(a). In such event, the right of any Holder to include his Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided
herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting by the Company.
Notwithstanding any other provision of this Section 2.2, if the underwriter(s) advise(s) the Company in writing that marketing factors require a limitation of the number of securities to be underwritten then the Company shall so advise all
Holders of Registrable Securities which would otherwise be registered and underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter(s) and
allocated among the Holders of Registrable Securities on a pro rata basis according to the number of Registrable Securities then outstanding held by each Holder requesting registration (including the Initiating Holders); provided,
however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting and
registration. Any Registrable Securities excluded and withdrawn from such underwriting shall be withdrawn from the registration. 
  

 - 5 - 

 (c) Maximum Number of Demand Registrations. The Company is obligated to
effect only three (3) such registrations pursuant to this Section 2.2. 
 (d) Deferral. Notwithstanding the foregoing, if
the Company shall furnish to Holders requesting the filing of a registration statement pursuant to this Section 2.2, a certificate signed by the President or Chief Executive Officer of the Company stating that in the good faith judgment of the
Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, then the Company
shall have the right to defer such filing for a period of not more than 120 days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve
(12) month period. 
 (e) Expenses. All expenses incurred in connection with a registration pursuant to this Section 2.2,
including without limitation all registration and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company, and reasonable fees and disbursements of one counsel for the selling Holders (but excluding
underwriters’ discounts and commissions), shall be borne by the Company. Each Holder participating in a registration pursuant to this Section 2.2 shall bear such Holder’s proportionate share (based on the total number of shares sold
in such registration other than for the account of the Company) of all discounts, commissions or other amounts payable to underwriters or brokers in connection with such offering. Notwithstanding the foregoing, the Company shall not be required to
pay for any expenses of any registration proceeding begun pursuant to this Section 2.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered, unless the
Holders of a majority of the Registrable Securities then outstanding agree to forfeit their right to one (1) demand registration pursuant to this Section 2.2 (in which case such right shall be forfeited by all Holders of Registrable
Securities); provided, however, that (i) if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company not known to the Holders at the time of
their request for such registration and have withdrawn their request for registration with reasonable promptness after learning of such material adverse change, or (ii) if, after the Company has deferred the filing of a registration statement
in accordance with subsection 2.2(d), the Holders have learned of a material adverse change in general market conditions for the Company’s Registrable Securities not known to the Holders at the time of such Company deferral and have withdrawn
their request for registration with reasonable promptness after learning of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to this Section 2.2. 

2.3 Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at least thirty (30) days
prior to filing any registration statement under the Securities Act for purposes of effecting a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the
Company, but excluding registration statements relating to any registration under Section 2.2 or Section 2.4 of this Agreement or to any employee 

  

 - 6 - 

 
benefit plan or a corporate reorganization) and will afford each such Holder an opportunity to include in such registration statement all or any part of the
Registrable Securities then held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by such Holder shall, within twenty (20) days after receipt of the
above-described notice from the Company, so notify the Company in writing, and in such notice shall inform the Company of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to
include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or
registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. No shareholder of the Company shall be granted registration rights equal to or senior to those of
the holders of the Registrable Securities without the consent of the holders of at least a majority of the Registrable Securities then outstanding. 
 (a) Underwriting. If a registration statement under which the Company gives notice under this Section 2.3 is for an underwritten offering, then the Company shall so advise the Holders of Registrable
Securities. In such event, the right of any such Holder’s Registrable Securities to be included in a registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the
inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in
customary form with the managing underwriter or underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Agreement, if the managing underwriter determine(s) in good faith that marketing factors require a limitation
of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares (including Registrable Securities) from the registration and the underwriting, and the number of shares that may be included in the registration and the
underwriting shall be allocated, first, to the Company, and second, to each of the Holders requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based on the total number of Registrable
Securities then held by each such Holder; provided however, that the right of the underwriters to exclude shares (including Registrable Securities) from the registration and underwriting as described above shall be restricted so that the
number of Registrable Securities included in any such registration is not reduced below twenty percent (20%) of the shares included in the registration, except for a registration relating to the Company’s initial public offering from which
all Registrable Securities may be excluded. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least ten (10) business
days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership or corporation, the
partners, retired partners and shareholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder”,
and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder”, as defined in this
sentence. 
  

 - 7 - 

 (b) Expenses. All expenses incurred in connection with a registration pursuant to this
Section 2.3 (excluding underwriters’ and brokers’ discounts and commissions), including, without limitation all federal and “blue sky” registration and qualification fees, printers’ and accounting fees, fees and
disbursements of counsel for the Company and reasonable fees and disbursements of one counsel for the selling Holders shall be borne by the Company. 
 2.4 Form S-3 Registration. In case the Company shall receive from any Holder or Holders of at least twenty percent (20%) of all Registrable Securities then outstanding a written request or
requests that the Company effect a registration on Form S-3 (or any other successor Form S-3) or any similar short form registration statement and any related qualification or compliance with respect to all or a part of the Registrable Securities
owned by such Holder or Holders, then the Company will: 
 (a) Notice. Promptly give written notice of the proposed registration and
the Holder’s or Holders’ request therefor, and any related qualification or compliance, to all other Holders of Registrable Securities; and 
 (b) Registration. As soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such
portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a
written request given within twenty (20) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant
to this Section 2.4: 
 (1) if Form S-3 (or any successor or similar short form) is not available for such offering by the Holders;

 (2) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose
to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than One Million Dollars ($1,000,000); 
 (3) if the Company shall furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company stating that in the good faith judgment of the Board of Directors of the Company, it
would be seriously detrimental to the Company and its shareholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement no more than
once during any nine month period for a period of not more than 120 days after receipt of the request of the Holder or Holders under this Section 2.4; 
 (4) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one (1) registration on Form S-3 for the Holders pursuant to this Section 2.4; or

  

 - 8 - 

 (5) in any particular jurisdiction in which the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance. 
 (c) Expenses.
Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the Registrable Securities and other securities so requested to be registered pursuant to this Section 2.4 as soon as practicable after receipt of
the request or requests of the Holders for such registration. The Company shall pay all expenses incurred in connection with each registration requested pursuant to this Section 2.4 (excluding underwriters’ or brokers’ discounts and
commissions), including without limitation all filing, registration and qualification, printers’ and accounting fees and the reasonable fees and disbursements of one counsel for the selling Holder or Holders and counsel for the Company.

 (d) Not Demand Registration. Form S-3 registrations shall not be deemed to be demand registrations as described in
Section 2.2 above. 
 2.5 Obligations of the Company. Whenever required to effect the registration of any
Registrable Securities under this Agreement, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC
a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for up to ninety (90) days. 
 (b) Prepare and file with the SEC such amendments
and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered
by such registration statement. 
 (c) Furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in
conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities owned by them that are included in such registration. 
 (d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of
such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be
delivered under the Securities Act of the happening of any event as a result of which the 

  

 - 9 - 

 
prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (g) Furnish, at the request of any Holder requesting registration of Registrable Securities, on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters,
or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated as of such date, of the counsel representing the Company for
the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the
underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a “comfort” letter dated as of such date, from the independent certified public accountants of the Company, in form and substance as
is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any,
and to the Holders requesting registration of Registrable Securities. 
 2.6 Furnish Information. It shall be a condition
precedent to the obligations of the Company to take any action pursuant to Sections 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them, and the
intended method of disposition of such securities as shall be required to timely effect the registration of their Registrable Securities. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2. 
 2.8 Indemnification. In the event any Registrable Securities are included
in a registration statement under Sections 2.2, 2.3 or 2.4: 
 (a) By the Company. To the extent permitted by law, the
Company will indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter
within the meaning of the Securities Act or the Securities Exchange Act of 1934, as amended, (the “1934 Act”), against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the
Securities Act, the l934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively
a “Violation”): 
 (i) any untrue statement or alleged untrue statement of a material fact contained in such
registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; 
  

 - 10 - 

 (ii) the omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading, or 
 (iii) any violation or alleged violation by
the Company of the Securities Act, the 1934 Act, any federal or state securities law or any rule or regulation promulgated under the Securities Act, the 1934 Act or any federal or state securities law in connection with the offering covered by such
registration statement; 
 and the Company will reimburse each such Holder, partner, member, officer or director, underwriter or controlling person for any
legal or other expenses reasonably incurred by them, as incurred, in connection with investigating or defending any such loss, claim, damage, liability or action; provided however, that the indemnity agreement contained in this subsection
2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be
liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in
connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling person of such Holder. 
 (b) By Selling Holders. To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who have signed the registration statement, each person,
if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, member, directors or officers or any
person who controls such Holder within the meaning of the Securities Act or the 1934 Act (on a several and not joint basis), against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer,
controlling person, underwriter or other such Holder, partner, member or director, officer or controlling person of such other Holder may become subject under the Securities Act, the 1934 Act or other federal or state law, insofar as such losses,
claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling person, underwriter or
other Holder, partner, member, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity
agreement contained in this subsection 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld; and provided further, that the total amounts payable in indemnity by a Holder under this Section 2.8(b) in respect of any Violation shall not exceed the net proceeds received by such Holder in the sale of its
Registrable Securities in the registered offering out of which such Violation arises. 
  

 - 11 - 

 (c) Notice. Promptly after receipt by an indemnified party under this Section 2.8 of notice
of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict of interests between such indemnified party and any other party represented by such counsel in such proceeding. The
failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.

 (d) Defect Eliminated in Final Prospectus. The foregoing indemnity agreements of the Company and Holders are
subject to the condition that, insofar as they relate to any Violation made in a preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the registration statement in question becomes effective or
the amended prospectus filed with the SEC pursuant to SEC Rule 424(b) (the “Final Prospectus”), such indemnity agreement shall not inure to the benefit of any person if a copy of the Final Prospectus was furnished to the indemnified
party and was not furnished to the person asserting the loss, liability, claim or damage at or prior to the time such action is required by the Securities Act; provided, however, that this condition shall only apply where the
indemnified party had an obligation to provide the Final Prospectus to such person. 
 (e) Contribution. If the indemnification
provided for in this Section 2.8 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to
state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission;
provided, that in no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering of its Registrable Securities received by such Holder. Notwithstanding 

  

 - 12 - 

 
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with
the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided, however, that in no event shall the provisions of such underwriting agreement impose
potential liability on a Holder for indemnity or contribution in excess of the net proceeds from the offering of its Registrable Securities received by such Holder; provided, further, however, the provisions on indemnification
and contribution contained in the underwriting agreement shall not be deemed to be in conflict with the foregoing provisions solely by virtue of the fact that the underwriting agreement is silent on them. 
 (f) Survival. The obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable
Securities in a registration statement, and otherwise. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement
which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 
 2.9 “Market Stand-Off” Agreement. Each Holder hereby agrees that it shall not, to the extent requested by the Company or an underwriter
of securities of the Company, sell or otherwise transfer or dispose of any Registrable Securities or other shares of stock of the Company then owned by such Holder (other than shares purchased on the public market after the effective date of a
registration statement of the Company filed under the Securities Act or shares purchased from the Company’s underwriters in an underwritten public offering pursuant to such a registration statement), other than to donees or partners of the
Holder who agree to be similarly bound and other than those included in the registration, for up to one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act;
provided, however, that: 
 (a) such agreement shall be applicable only to the first such registration statement of the Company
which covers securities to be sold on its behalf to the public in an underwritten offering but not to Registrable Securities sold pursuant to such registration statement; 
 (b) all executive officers and directors of the Company then holding Common Stock of the Company enter into similar agreements; and 
 (c) such agreement prohibits the Company or the underwriters from selectively releasing certain persons from the market stand-off provisions.

 In order to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing
the shares subject to this Section and to impose stop transfer instructions with respect to the Registrable Securities and such other shares of stock of each Holder (and the shares or securities of every other person subject to the foregoing
restriction) until the end of such period. 
  

 - 13 - 

 Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the
Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the
Company, each Holder shall provide, within fifteen (15) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities
pursuant to a registration statement filed under the Securities Act. 
 2.10 Rule 144 Reporting. With a view to making
available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Registrable Securities to the public without registration, after such time as a public market exists for the Common Stock of the
Company, the Company agrees to: 
 (a) Make and keep public information available, as those terms are understood and defined in Rule 144
under the Securities Act, at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 
 (b) Use its best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act
and the 1934 Act (at any time after it has become subject to such reporting requirements); and 
 (c) So long as a Holder owns any
Registrable Securities, to furnish to the Holder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time after 90 days after the effective date of the first
registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the 1934 Act (at any time after it has become subject to the reporting requirements of the 1934 Act), a copy of the
most recent annual or quarterly report of the Company, and such other reports and documents of the Company as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such
securities without registration (at any time after the Company has become subject to the reporting requirements of the 1934 Act). 
 2.11
Limitations on Subsequent Registration Rights. The Company shall not, without the prior written consent of Investors holding at least two-thirds (2/3) of the Investors’ Shares (as defined in Section 4.2 below) then held by all
Investors, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which grants such holder or prospective holder rights to include securities of the Company in any registration
statement of the Company, provided, however that no such consent shall be required for the Company to grant “piggyback” registration rights that are subordinated to those of holders of Registrable Securities with respect to underwriter
cutbacks. 
 2.12 Termination of the Company’s Obligations. The Company shall have no obligations pursuant to
Sections 2.2 through 2.4 with respect to: (i) any request or requests for registration made by any Holder on a date more than seven (7) years after the closing date of the Company’s initial public offering; or (ii) any
Registrable Securities proposed to be sold by a Holder in a 

  

 - 14 - 

 
registration pursuant to Section 2.2, 2.3 or 2.4 if, in the opinion of counsel to the Company, all such Registrable Securities proposed to be sold by a
Holder may be sold in a three-month period without registration under the Securities Act pursuant to Rule 144 under the Securities Act. 
  

	 	3.	RIGHT OF FIRST REFUSAL. 

 3.1 General.
Each Holder (as defined in subsection 2.1(d)) and any party to whom such Holder’s rights under this Section 3 have been duly assigned in accordance with subsection 4.1(b) (each such Holder or assignee being hereinafter referred to
as a “Rights Holder”) has the right of first refusal to purchase such Rights Holder’s Pro Rata Share (as defined below in this Section 3.1), of all (or any part) of any “New Securities” (as defined in
Section 3.2 below) that the Company may from time to time issue after the date of this Agreement. A Rights Holder’s “Pro Rata Share” for purposes of the right of first refusal granted under this Section 3.1 is the
ratio of (a) the number of Registrable Securities as to which such Rights Holder is the Holder (and/or is deemed to be the Holder under subsection 2.1(d)), to (b) a number of shares of Common Stock of the Company equal to the sum of
(1) the total number of shares of Common Stock of the Company then outstanding, plus (2) the total number of shares of Common Stock of the Company into which all then outstanding shares of Preferred Stock of the Company are then
convertible, plus (3) the number of shares of Common Stock of the Company issuable upon exercise of any outstanding options, warrants or other convertible securities of the Company or upon conversion of any convertible securities that are
issuable upon the exercise of any of the foregoing. 
 3.2 New Securities. “New Securities” shall mean any
Common Stock or Preferred Stock of the Company, whether now authorized or not, and rights, options or warrants to purchase such Common Stock or Preferred Stock, and securities of any type whatsoever that are, or may become, convertible or
exchangeable into such Common Stock or Preferred Stock; provided, however, that the term “New Securities” does not include: 
 (a) any shares of the Company’s Common Stock (and/or options or warrants therefor) issued to employees, officers, or directors of, or contractors, consultants or advisors to the Company pursuant to stock purchase
agreements or stock option plans, stock bonuses or awards or other arrangements that are approved by the Board of Directors of the Company (the “Board”); 
 (b) any securities issuable upon conversion of or with respect to any shares of Preferred Stock or Common Stock or other securities
issuable upon conversion thereof; 
 (c) any securities (i) issuable upon exercise of any options, warrants or rights to
purchase any securities of the Company outstanding on the date of this Agreement (“Warrant Securities”) and any securities issuable upon the conversion of any Warrant Securities or (ii) upon the exercise or conversion of any
other securities, if such other securities were first offered to the Rights Holders hereunder; 
  

 - 15 - 

 (d) the Series F Warrants and any securities directly or indirectly issuable upon
exercise thereof; 
 (e) shares of the Company’s Common Stock or Preferred Stock issued in connection with any stock
split or stock dividend; 
 (f) securities offered by the Company to the public pursuant to a registration statement filed
under the Securities Act; 
 (g) any shares of the Company’s Common Stock or Preferred Stock (and/or options or warrants
therefor) issued or issuable to parties in connection with such parties’ providing the Company with equipment leases, real property leases, loans, credit lines, guaranties of indebtedness, cash price reductions or similar financing pursuant to
contracts or other arrangements approved by the Board (including, for so long as the provisions of Article VI, subsection 4.5(a)(i), (ii), (iii) or (iv) of the Articles of Incorporation, as amended are in full force and effect, at least
80% of the members of the Board); or 
 (h) any shares of the Company’s Common Stock (or options, warrants or rights
directly or indirectly exercisable therefore and the underlying Common Stock) issued to commercial or strategic partners of the Company in connection with transactions that are not entered into primarily for purposes of raising working capital or
that are issued in connection with acquisitions by the Company of assets of third parties or of other companies, in all such cases pursuant to contracts or other arrangements that are unanimously approved by the Board. 
 3.3 Procedures. In the event that the Company proposes to undertake an issuance of New Securities, it shall give to each Rights Holder written
notice of its intention to issue New Securities (the “Notice”), describing the type of New Securities and the price and the general terms upon which the Company proposes to issue such New Securities. Each Rights Holder shall have
twenty (20) days from the date of mailing of any such Notice to agree in writing to purchase such Rights Holder’s Pro Rata Share of such New Securities for the price and upon the general terms specified in the Notice by giving written
notice to the Company and stating therein the quantity of New Securities to be purchased (not to exceed such Rights Holder’s Pro Rata Share). If any Rights Holder fails to so agree in writing within such twenty (20) day period to
purchase such Rights Holder’s full Pro Rata Share of an offering of New Securities (a “Nonpurchasing Holder”), then such Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of his Pro Rata Share of such
New Securities that he did not so agree to purchase and the Company shall promptly give each Rights Holder who has timely agreed to purchase his full Pro Rata Share of such offering of New Securities (a “Purchasing Holder”) written
notice of the failure of any Nonpurchasing Holder to purchase such Nonpurchasing Rights Holder’s full Pro Rata Share of such offering of New Securities (the “Overallotment Notice”). Each Purchasing Holder shall have a right of
overallotment such that such Purchasing Holder may agree to purchase a portion of the Nonpurchasing Holders’ unpurchased Pro Rata Shares of such offering on a pro rata basis according to the relative Pro Rata Shares of the Purchasing Rights
Holders, at any time within five (5) days after receiving the Overallotment Notice. 
  

 - 16 - 

 3.4 Failure to Exercise. In the event that the Rights Holders fail to timely exercise in
full the right of first refusal provided for in Section 3.3, then the Company shall have 120 days after the expiration of the time periods provided for in Section 3.3 to sell the New Securities with respect to which the Rights
Holders’ rights of first refusal hereunder were not exercised, at a price and upon general terms not materially more favorable to the purchasers thereof than specified in the Company’s Notice to the Rights Holders. In the event that the
Company has not issued and sold the New Securities within such 120 day period, then the Company shall not thereafter issue or sell any New Securities without again first offering such New Securities to the Rights Holders pursuant to this
Section 3. 
 3.5 Termination. This right of first refusal shall terminate upon the earlier of (a) the closing of the first
underwritten sale of Common Stock of the Company to the public pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act, covering the offer and sale of Common Stock to the public as a result of
which all outstanding shares of the Company’s Preferred Stock are converted into Common Stock (a “Qualified Public Offering”), or (b) (1) the acquisition of all or substantially all the assets of the Company or
(2) an acquisition of the Company by another corporation or entity by consolidation, merger or other reorganization in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after
such transaction, securities representing less than fifty percent (50%) or more of the voting power of the corporation or other entity surviving such transaction on account of shares of the Company’s stock held by them immediately prior to
such consolidation, merger or other reorganization. 
 3.6 Special Right of First Refusal. To the extent that the Company does not
exercise any right of first refusal it may have to repurchase shares of its outstanding Common Stock in the event that the holder of such shares of Common Stock (a “Common Stock Holder”) gives the Company notice of an intention to
transfer such shares (“Offered Shares”) to a third party (a “Transfer Notice”), the Company shall, to the extent permitted by the applicable contracts and law, assign to each of the Rights Holders its “Pro Rata
Share” (as defined below in this Section 3.6) of the Company’s right of first refusal and follow the procedures set forth below in this Section 3.6. For purposes of this Section 3.6, Rights Holder’s “Pro Rata
Share” is the ratio of (a) the number of Registrable Securities as to which such Rights Holder is the Holder (and/or is deemed to be the Holder under subsection 2.1(d)), to (b) the number of Registrable Securities as to which all
Rights Holders are the Holders (and/or are deemed to be the Holders under subsection 2.1(d)) 
 (a) Procedures. In the event that the
Company does not elect to exercise its right of first refusals, then within ten (10) days of receipt of a Transfer Notice, the Company shall give to each Rights Holder written notice (a “Section 3.6 Notice”) of the receipt of
such Transfer Notice, which shall also set forth all of the information provided by the Common Stock Holder to the Company regarding the proposed transferee and the offered price for the Offered Shares, and include the name and address of the Common
Stock Holder, a statement of the number of Offered Shares being made available to the Rights Holders (after taking deducting those which the Company intends to repurchase). Each Rights Holder shall have fifteen (15) days from the date of
mailing of any such Section 3.6 Notice to agree in writing to purchase such Rights Holder’s Pro Rata Share of such Offered Shares for the price and upon the general terms specified in the Section 3.6 Notice by giving written notice to
the Company and the Common 

  

 - 17 - 

 
Stock Holder and stating therein the quantity of New Securities to be purchased (not to exceed such Rights Holder’s Pro Rata Share). If any Rights
Holder fails to so agree in writing within such fifteen (15) day period to purchase such Rights Holder’s full Pro Rata Share of an offering of Offered Shares, then such Rights Holder shall forfeit the right hereunder to purchase that
part of his Pro Rata Share of such Offered Shares that he did not so agree to purchase. 
 (b) Termination. This right of first
refusal shall terminate at the same time that the right of first refusal provided for in Section 3.1 terminates pursuant to the provisions of Section 3.5. 
  

	 	4.	ASSIGNMENT AND AMENDMENT. 

 4.1
Assignment. Notwithstanding anything herein to the contrary: 
 (a) Information Rights. The rights of a Major Investor
under Section 1.1 or 1.2 hereof may be assigned only to a party who acquires from an Investor (or an Investor’s permitted assigns) at least that number of shares of Common Stock or Preferred Stock and/or an equivalent number (on an
as-converted basis) of shares of Conversion Stock described in Section 1.1 necessary to qualify as a “Major Investor”; provided, however that no party may be assigned any of the foregoing rights unless the Company is
given written notice by the assigning party at the time of such assignment stating the name and address of the assignee and identifying the securities of the Company as to which the rights in question are being assigned; and provided,
further, that any such assignee shall receive such assigned rights subject to all the terms and conditions of this Agreement, including without limitation the provisions of this Section 4, by agreeing in a writing satisfactory to the
Company to be bound by the terms hereof. 
 (b) Registration Rights and Rights of First Refusal. The registration rights of a
Holder under Section 2 hereof and/or the rights of first refusal of a Holder under Section 3 hereof may be assigned by a Holder to a transferee or assignee of Registrable Securities (who has received such Registrable Securities in
accordance with the terms and conditions relating to transfers of shares set forth in the applicable Stock Purchase Agreement) which (a) is a subsidiary, parent, general partner, limited partner, retired partner, member or retired member of a
Holder, (b) is a Holder’s family member or trust for the benefit or an individual Holder, (c) is an affiliate of a Holder (including, as to a Holder that is a venture capital fund, an affiliated or co-managed fund of such Holder), or
(d) acquires at least 50,000 shares of stock issued under the Stock Purchase Agreements, and/or upon exercise of any Warrants and/or an equivalent number (on an as-converted basis) of Registrable Securities issued upon conversion thereof;
provided, however that no party may be assigned any of the foregoing rights unless the Company is given written notice by the assigning party at the time of such assignment stating the name and address of the assignee and identifying
the securities of the Company as to which the rights in question are being assigned; and provided further that any such assignee shall receive such assigned rights subject to all the terms and conditions of this Agreement, including without
limitation the provisions of this Section 4, by agreeing in a writing satisfactory to the Company to be bound by the terms hereof. 
  

 - 18 - 

 4.2 Amendment of Rights. 
 (a) Any provision of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company and Investors (and/or any of their permitted successors or assigns) holding shares of Common Stock and Preferred Stock purchased under the Stock Purchase Agreements and/or
Conversion Stock representing and/or convertible into at least two-thirds (2/3) of all the Investors’ Shares (as defined below). As used herein, the term “Investors’ Shares” shall mean the shares of Common Stock
then issuable upon conversion of all then outstanding shares of Preferred Stock issued under the Stock Purchase Agreements plus all then outstanding shares of Conversion Stock that were issued upon the conversion of any shares of Preferred Stock
issued under the Stock Purchase Agreements. Any amendment or waiver effected in accordance with this Section 4.2 shall be binding upon each Investor, each Holder, each permitted successor or assignee of such Investor or Holder and the Company.
Notwithstanding the foregoing, if any amendment or waiver materially and adversely affects the express rights hereunder of an Investor who does not consent in writing thereto (a “Nonconsenting Investor”) in a manner that is
materially different from the corresponding affect, if any, on the express rights hereunder of other Investors, then such amendment or waiver shall not be effective as against the Nonconsenting Investor. 
 (b) Notwithstanding anything herein to the contrary, if pursuant to Section 2.3 of the Series F Agreement, additional parties purchase shares of
Series F Stock pursuant to the Series F Agreement, as amended from time to time, as “New Investors” thereunder, then each such New Investor shall become a party to this Agreement as an “Investor” hereunder, without the need for
any consent, approval or signature of any Investor hereunder when such New Investor has both: (i) purchased shares of Series F Stock under the Series F Agreement, as amended from time to time, and paid the Company all consideration payable for
such shares, and (ii) executed one or more counterpart signature pages to this Agreement as an “Investor”, with the Company’s consent. 
  

	 	5.	GENERAL PROVISIONS. 

 5.1
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon (i) personal delivery to the party to be notified, (ii) deposit with the
United States Post Office, by registered or certified mail, postage prepaid; provided, however, that registered or certified mail shall not be used to effectuate the delivery of any such notice to addresses outside the United States, or
(iii) delivery to an express courier service, fees prepaid, and addressed to the party to be notified at the address indicated for such party on Exhibit A or, in the case of the Company, at 1400 N. Shoreline Boulevard, #A-8, Mountain
View, CA 94043, Attn. Cary Cole, President, or at such other address as any party or the Company may designate by giving ten (10) days advance written notice to all other parties. 
 5.2 Entire Agreement. This Agreement, together with all the Exhibits hereto, constitutes and contains the entire agreement and understanding
of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings, duties or obligations between the parties respecting the subject matter hereof, including under the
Prior Rights Agreement. 
  

 - 19 - 

 5.3 Governing Law. This Agreement shall be governed by and construed exclusively in
accordance with the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, excluding that body of law relating to conflict of laws and choice of law.

 5.4 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such
provision(s) shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms. 
 5.5 Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any person, other than the parties hereto and
their successors and assigns, any rights or remedies under or by reason of this Agreement. 
 5.6 Successors and Assigns.
Subject to the provisions of Section 4, the provisions of this Agreement shall inure to the benefit of, and shall be binding upon, the successors and permitted assigns of the parties hereto. 
 5.7 Captions. The captions to sections of this Agreement have been inserted for identification and reference purposes only and shall not be used
to construe or interpret this Agreement. 
 5.8 Counterparts. This Agreement may be executed in counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. 
 5.9
Costs And Attorneys’ Fees. In the event that any action, suit or other proceeding is instituted concerning or arising out of this Agreement or any transaction contemplated hereunder, the prevailing party shall recover all
of such party’s costs and attorneys’ fees incurred in each such action, suit or other proceeding, including any and all appeals or petitions therefrom. 
 5.10 Adjustments for Stock Splits, Etc. Wherever in this Agreement there is a reference to a specific number of shares of Common Stock or Preferred Stock of the Company of any class or
series, then, upon the occurrence of any subdivision, combination or stock dividend of such class or series of stock, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect the affect
on the outstanding shares of such class or series of stock by such subdivision, combination or stock dividend. 
 5.11 Delays or
Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor
shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. All remedies, either under this Agreement, by law, or otherwise
afforded to any party, shall be cumulative and not alternative. 
  

 - 20 - 

 5.12 Aggregation of Stock. All shares held or acquired by affiliated entities or persons
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. For purposes of this Agreement, Oakwood Medical Investors III (QP), L.L.C., Oakwood Medical Investors III, L.L.C. and Community
Investment Partners V L.P., L.L.P. shall be considered affiliated entities. 
 5.13
Prior Rights Agreement Superseded/Waiver of Rights of First Refusal. Pursuant to Section 4.2 of the Prior Rights Agreement, the undersigned parties who are parties to such Prior Rights Agreement hereby (i) amend and
restate the Prior Rights Agreement to read in its entirety as set forth in this Agreement, all with the intent and effect that the Prior Rights Agreement shall be hereby be terminated and entirely replaced and superseded by this Agreement and
(ii) waive, on behalf of each “Holder” (as defined in the Prior Rights Agreement), the application of the right of first refusal set forth in Section 3 of the Prior Rights Agreement to the issuance of shares of Series F Stock and
warrants exercisable for shares of Series F Stock pursuant to the Series F Agreement and the shares of Series F Preferred Stock issuable upon exercise of such warrants. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

 - 21 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

  

			
	 THE COMPANY:

	
	 BRONCUS TECHNOLOGIES, INC.

	 A California corporation

		
	 By:
	 	 /s/ Cary Cole

		 	Cary Cole, President

  

 [SIGNATURE PAGE TO FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 BETWEEN BRONCUS TECHNOLOGIES, INC. AND INVESTORS] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

					
	 Menlo Ventures VII, L.P.

	 By:
	 	 MV Management VII, LLC, its General

	 Partner

			
		 	By:	 	 /s/ John W. Jarve

		 		 	John W. Jarve, Managing Member
		 		 	(Please Print Name)
	
	 Menlo Entrepreneurs Fund VII, L.P.

	 By:
	 	 MV Management VII, LLC, its General

	 Partner

			
		 	By:	 	 /s/ John W. Jarve

		 		 	John W. Jarve, Managing Member
		 		 	(Please Print Name)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
 General Mills Group Trust 
  

			
	 By:
	 	 /s/ Daralyn Peifer

		 	(Signature)
		
		 	Daralyn Peifer
		 	(Print Name)
		
		 	Executive Secretary of the General
		 	Mills, Inc. Benefit Finance Committee
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	HBM BIOCAPTIAL (EUR) L.P.
	By:	 	HBM BioCapital Ltd.
	Its:	 	General Partner
	
	 /s/ John Arnold

	By:	 	John Arnold
	Its:	 	Director
	
	HBM BIOCAPTIAL (USD) L.P.
	By:	 	HBM BioCapital Ltd.
	Its:	 	General Partner
	
	 /s/ John Arnold

	By:	 	John Arnold
	Its:	 	Director
	
	HBM BIOVENTURES (CAYMAN) LTD.
	By:	 	HBM BioCapital Ltd.
	Its:	 	General Partner
	
	 /s/ John Arnold

	By:	 	John Arnold
	Its:	 	Director

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	JAIC-Henson MedFocus Fund, LLC
		
	By:	 	 /s/ David Richards

	Name:	 	David Richards
	Title:	 	CFO
	
	JAIC-Henson MedFocus Fund II, LLC
		
	By:	 	 /s/ David Richards

	Name:	 	David Richards
	Title:	 	CFO
	
	JAIC-Henson MedFocus Accelerator Fund, LLC
		
	By:	 	 /s/ David Richards

	Name:	 	David Richards
	Title:	 	CFO
	
	HBM-Henson MedFocus, LLC
		
	By:	 	 /s/ David Richards

	Name:	 	David Richards
	Title:	 	CFO

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Bio-Star Private Equity Fund, LLC
		
	 By:
	 	 /s/ David Richards

	 Name:
	 	David Richards
	 Title:
	 	CFO
	
	 Bio-Star Private Equity Fund FP, LLC

		
	 By:
	 	 /s/ David Richards

	 Name:
	 	David Richards
	 Title:
	 	CFO

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

	
	SightLine Healthcare Fund III, L.P.
	
	 /s/ Buzz Benson

	 (Signature)

	
	 Buzz Benson

	 (Print Name)

	
	  

	 (Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
 SightLine Healthcare Fund III, L.P. 
  

			
		 	

		 	(Signature)
		
		 	  

		 	(Print Name)
		
		 	  

		 	(Print Title)

  

			
	 SightLine Healthcare Vintage Fund, L.P.

	 By:
	 	SightLine Vintage Management, LLC
		
		 	 /s/ Maureen Harder

		 	(Signature)
		
		 	Maureen Harder
		 	(Print Name)
		
		 	Managing Director of SightLine Partners LLC
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	 Rockport Venture Fund I, LP

		
	 By:
	 	 /s/ Thomas R. Bassinger

		 	(Signature)
		
		 	Thomas R. Bassinger
		 	(Print Name)
		
		 	General Partner
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
 Abingworth Bioventures IV L.P. 
 acting by its maanger, Abingworth Management Limited 
  

			
	 By:
	 	 /s/ James Abell

		 	(Signature)
		
		 	James Abell
		 	(Print Name)
		
		 	Director
		 	(Print Title)

 Abingworth Bioventures IV Executives L.P. 
 acting by its maanger, Abingworth Management Limited 
  

			
	 By:
	 	 /s/ James Abell

		 	(Signature)
		
		 	James Abell
		 	(Print Name)
		
		 	Director
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	 F&W Investments 2000

		
	 By:
	 	 /s/ Laird H. Simons III

		 	Laird H. Simons III
		
		 	Partner
		 	(Print Title)
	
	 F&W Investments LLC - Series 2001

		
	 By:
	 	 /s/ Laird H. Simons III

		 	Laird H. Simons III
		
		 	Managing Member
		 	(Print Title)
	
	 F&W Investments LLC - Series 2003

		
	 By:
	 	 /s/ Laird H. Simons III

		 	Laird H. Simons III
		
		 	Managing Member
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	F&W Investments 2000
		
	By:	 	  

		 	Laird H. Simons III
		
		 	  

		 	(Print Title)
	
	F&W Investments LLC - Series 2001
		
	By:	 	  

		 	Laird H. Simons III
		
		 	  

		 	(Print Title)
	
	F&W Investments LLC - Series 2003
		
	By:	 	  

		 	Laird H. Simons III
		
		 	  

		 	(Print Title)
	
	F&W Investments LLC - Series 2006
		
	By:	 	 /s/ Laird H. Simons III

		 	Laird H. Simons III
		
		 	 Managing Member

		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Private Life GmbH & Co. KG
		
	 By:
	 	 /s/ Diefer Reinhardt

		
	 By:
	 	 /s/ Erich Waller

		
	 Name:
	 	David Richards
		
	 Name:
	 	Erich Waller
		
	 Title:
	 	(Managing Partners)
	
	 Private Life BioMed AG

		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	 Private Life GmbH & Co. KG

		
	 By:
	 	  

		
	 Name:
	 	  

		
	 Title:
	 	  

	
	 Private Life BioMed AG

		
	 By:
	 	 /s/ Marie M. ILLEGIBLE

		
	 By:
	 	 /s/

		
	 Name:
	 	Marie M. ILLEGIBLE
		
	 Name:
	 	  

		
	 Title:
	 	(Managing Directors)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	By:	 	 /s/ David Auth

		 	(Signature)
		
		 	David Auth
		 	(Print Name)
		
		 	  

		 	(Print Title)
		
	By:	 	  

		 	(Signature)
		
		 	  

		 	(Print Name)
		
		 	  

		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Boston Scientific Corporation
		
	By:	 	 /s/ Lawrence Best

		 	(Signature)
		
		 	Lawrence Best
		 	(Print Name)
		
		 	Chief Financial Officer
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Charter Entrepreneurs Fund III, LLC
		
	By:	 	 /s/ A. Barr Dolan

		 	A. Barr Dolan, Managing Member
	
	Charter Ventures III, LLC
		
	By:	 	 /s/ A. Barr Dolan

		 	A. Barr Dolan, Managing Member

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Community Investment Partners IV L.P., LLLP
		
	By:	 	 /s/ Bret D. Kimes

		 	(Signature)
		
		 	Bret D. Kimes
		 	(Print Name)
		
		 	President
		 	(Print Title)
	
	Community Investment Partners V L.P., LLLP
		
	By:	 	 /s/ Bret D. Kimes

		 	(Signature)
		
		 	Bret D. Kimes
		 	(Print Name)
		
		 	President
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	GC&H Investments
		
	By:	 	 /s/ John L. Cardoza

		 	(Signature)
		
		 	John L. Cardoza
		 	(Print Name)
		
		 	Executive Partner
		 	(Print Title)
	
	GC&H Investments, LLC
		
	By:	 	 /s/ John L. Cardoza

		 	(Signature)
		
		 	John L. Cardoza
		 	(Print Name)
		
		 	Executive Partner
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	By:	 	 /s/ Charles Lombard

		 	(Signature)
		
		 	Charles Lombard
		 	(Print Name)
		
		 	  

		 	(Print Title)
		
	By:	 	  

		 	(Signature)
		
		 	  

		 	(Print Name)
		
		 	  

		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	MC2 Foundation
		
	By:	 	 /s/ Cary Cole

		 	(Signature)
		
		 	Cary Cole
		 	(Print Name)
		
		 	  

		 	(Print Title)
		
	By:	 	  

		 	(Signature)
		
		 	  

		 	(Print Name)
		
		 	  

		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Mitsui & Co. (U.S.A.), Inc.
		
	By:	 	 /s/ Kenichi Hori

		 	(Signature)
		
		 	Kenichi Hori
		 	(Print Name)
		
		 	Senior Vice President
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Oakwood Medical Investors III (QP), L.L.C.
		
	By:	 	 /s/ Raul E. Perez, M.D.

		 	(Signature)
		
		 	Raul E. Perez, M.D.
		 	(Print Name)
		
		 	President
		 	(Print Title)
	
	Oakwood Medical Investors III, L.L.C.
		
	By:	 	 /s/ Raul E. Perez, M.D.

		 	(Signature)
		
		 	Raul E. Perez, M.D.
		 	(Print Name)
		
		 	President
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

									
	Pacific Life Insurance Company	 		 	Pacific Life Insurance Company
					
	By:	 	 /s/ Samuel Tang
	 		 	By:	 	 /s/ Ronn C. Cornelius

		 	(Signature)	 		 		 	(Signature)
					
		 	Samuel Tang	 		 		 	Ronn C. Cornelius
		 	(Print Name)	 		 		 	(Print Name)
					
		 	AVP	 		 		 	AVP
		 	(Print Title)	 		 		 	(Print Title)
			
	Pacific Life and Annuity	 		 	Pacific Life and Annuity
					
	By:	 	 /s/ Samuel Tang
	 		 	By:	 	 /s/ Ronn C. Cornelius

		 	(Signature)	 		 		 	(Signature)
					
		 	Samuel Tang	 		 		 	Ronn C. Cornelius
		 	(Print Name)	 		 		 	(Print Name)
					
		 	AVP, Investment Mgmt. Div. & Asst. Sec.	 		 		 	AVP, Investment Mgmt. Div. & Asst. Sec.
		 	(Print Title)	 		 		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Pequot Private Equity Fund II, L.P.
	By:	 	Pequot Capital Management, Inc.
		 	Its Investment Manager
		
		 	 /s/ Carlos Rodrigues

		 	(Signature)
		
		 	Carlos Rodrigues
		 	(Print Name)
		
		 	Chief Financial Officer
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	By:	 	 /s/ Thomas A. Raffin

		 	(Signature)
		
		 	Thomas A. Raffin
		 	(Print Name)
		
		 	TTES Raffin Revocable Trust 6/11/93
		 	(Print Title)
		
	By:	 	 /s/ P. Michele Raffin

		 	(Signature)
		
		 	P. Michele Raffin
		 	(Print Name)
		
		 	TTES Raffin Revocable Trust 6/11/93
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Venture Lending & Leasing III, LLC
		
	By:	 	 /s/ Martin Eng

		 	(Signature)
		
		 	Martin Eng
		 	(Print Name)
		
		 	CFO
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 Investor Signature Pages 
 Second Closing 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Tenue Business S.A.
		
	By:	 	 /s/ Frank Oliver Zindle

		 	(Signature)
		
		 	Frank Oliver Zindle
		 	(Print Name)
		
		 	  

		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Global Strategic Investment Co., Ltd.
		
	By:	 	 /s/ Shih-Chien Yang

		 	(Signature)
		
		 	Shih-Chien Yang
		 	(Print Name)
		
		 	Chairman
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 Investor Signature Pages 
 Third Closing 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Biomedical Sciences Investment Fund Pte Ltd
		
	By:	 	 /s/ Chu Swee Yeok

		 	(Signature)
		
		 	Chu Swee Yeok
		 	(Print Name)
		
		 	Director
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 Investor Signature Pages 
 Fourth Closing 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Japan Asia Investment Co., Ltd.
		
	By:	 	 /s/ Toyoji Tatsaoka

		 	(Signature)
		
		 	Toyoji Tatsaoka
		 	(Print Name)
		
		 	President & CEO
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 Investor Signature Pages 
 Fifth Closing 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Shin Sheng Venture Capital Investment Corp.
	
	 /s/ Hsu Shan Ko

	By:	 	Hsu Shan Ko
	Its:	 	

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	FuYu Venture Capital Investment Corp.
	
	 /s/ Hsu Shan Ko

	By:	 	Hsu Shan Ko
	Its:	 	

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Alliance Investment Management Corp.
	
	 /s/ Hsu Shan Ko

	By:	 	Hsu Shan Ko
	Its:	 	

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 Investor Signature Pages 
 Sixth Closing 

 IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT as of the date first above written. 
 INVESTORS: 
  

			
	Saratoga Ventures IV LP
		
	By:	 	 /s/ Foster D. Hendrix

		 	(Signature)
		
		 	Foster D. Hendrix
		 	(Print Name)
		
		 	General Partner
		 	(Print Title)
	
	Saratoga Ventures V LP
		
	By:	 	 /s/ Foster D. Hendrix

		 	(Signature)
		
		 	Foster D. Hendrix
		 	(Print Name)
		
		 	General Partner
		 	(Print Title)

  

 [SIGNATURE PAGE TO BRONCUS TECHNOLOGIES, INC. 
 FIFTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT] 

 EXHIBIT A 
 INVESTORS 
  

						
	 Broncus Technologies, Inc.
	  			  	
	 Series F Price Per Share
	  	$	0.6578	  	
	 Shares Authorized in Purchase Agt.
	  	 	45,606,568	  	
			
	 Investor Name and Address
	  	Investment Amount	  	Series F Shares
	 Menlo Ventures VII, L.P.
 3000 Sand Hill Road
 Building 4, Suite 100
 Menlo Park, CA 94025
 Attn: DuBose Montgomery, Managing Director
 T: (650) 854-8540
 F: (650) 854-7059
	  	$	961,539.15	  	1,461,750
			
	 Menlo Entrepreneurs Fund VII, L.P.
 3000 Sand Hill Road
 Building 4, Suite 100
 Menlo Park, CA 94025
 Attn: DuBose Montgomery, Managing Director
 T: (650) 854-8540
 F: (650) 854-7059
	  	$	38,461.57	  	58,470
			
	 General Mills Group Trust
 General Mills, Inc.
 One General Mills Blvd.
 Minneapolis, MN 55426
 Attn: Daralyn Peifer
 T: (763) 764-3289
 F: (763) 764-7384
	  	$	120,000.49	  	182,427
			
	 HBM BioCapital (EUR) L.P.
 c/o HBM BioVentures (Cayman) Ltd.
 Attn: John Arnold
 PO Box 30852 SMB
 Eucalyptus Bldg., Crewe Road
 Grand Cayman, Cayman Islands
 Facsimile: (345) 946-8003
	  	$	1,494,000.63	  	2,271,208

  

 1 

						
	 HBM BioCapital (USD) L.P.
 c/o HBM BioVentures (Cayman) Ltd.
 Attn: John Arnold
 PO Box 30852 SMB
 Eucalyptus Bldg., Crewe Road
 Grand Cayman, Cayman Islands
 Facsimile: (345) 946-8003
	  	$	506,000.16	  	769,231
			
	 HBM BioVentures (Cayman) Ltd.
 Attn: John Arnold
 PO Box 30852 SMB
 Eucalyptus Bldg., Crewe Road
 Grand Cayman, Cayman Islands
 Facsimile: (345) 946-8003
	  	$	8,800,000.39	  	13,377,927
			
	 JAIC-Henson MedFocus Fund II, LLC
 Attn: David Richards
 13900 Alton Parkway, Suite 125
 Irvine, CA 92618
 Facsimile: (949) 581-4761
	  	$	100,000.08	  	152,022
			
	 JAIC-Henson MedFocus Accelerator Fund, LLC
 Attn: David Richards
 13900 Alton Parkway, Suite 125
 Irvine, CA 92618
 Facsimile: (949) 581-4761
	  	$	100,000.08	  	152,022
			
	 HBM-MedFocus, LLC
 Attn: David Richards
 13900 Alton Parkway, Suite 125
 Irvine, CA 92618
 Facsimile: (949) 581-4761
	  	$	150,000.11	  	228,033
			
	 Bio-Star Private Equity Fund, LLC
 Attn: David Richards
 13900 Alton Parkway, Suite 125
 Irvine, CA 92618
 Facsimile: (949) 581-4761
	  	$	424,000.12	  	644,573
			
	 Bio Star Private Equity Fund FP, LLC
 Attn: David Richards
 13900 Alton Parkway, Suite 125
 Irvine, CA 92618
 Facsimile: (949) 581-4761
	  	$	76,000.24	  	115,537

  

 2 

						
	 Sightline Healthcare Vintage Fund, L.P.
 Attn: Buzz Benson
 50 South 6th Street
 Minneapolis, MN 55402
 Facsimile: (612) 465-0620
	  	$	2,500,000.48	  	3,800,548
			
	 Sightline Healthcare Fund III, L.P.
 Attn: Buzz Benson
 50 South 6th Street
 Minneapolis, MN 55402
 Facsimile: (612) 465-0620
	  	$	500,000.36	  	760,110
			
	 Rockport Venture Fund I, LP
 Attn: Tom Bassinger, General Partner
 275 Cabot Street, Suite 10
 Beverly, MA 01915
	  	$	400,000.29	  	608,088
			
	 Abingworth Bioventures IV LP
 Attn: General Counsel/Company Secretary
 38 Jermyn Street
 London SW1Y 6DN
 United Kingdom
 Facsimile: 020 7534 1539
  
 Notices should also be sent to:
 Abingworth Management Inc.
 3000 Sand Hill Road, Bldg 4, Suite 135
 Menlo Park, CA 94025
 Attn: Jonathan MacQuitty
 Facsimile: (650) 926-9782
	  	$	7,931,975.40	  	12,058,339
			
	 Abingworth Bioventures IV Executives LP
 Attn: General Counsel/Company Secretary
 38 Jermyn Street
 London SW1Y 6DN
 United Kingdom
 Facsimile: 020 7534 1539
  
 Notices should also be sent to:
 Abingworth Management Inc.
 3000 Sand Hill Road, Bldg 4, Suite 135
 Menlo Park, CA
 Attn: Jonathan MacQuitty
 Facsimile: (650) 926-9782
	  	$	68,025.08	  	103,413

  

 3 

						
	 F&W Investments LLC - Series 2006
 Attn: Laird H. Simons III
 801 California Ave
 Mountain View, CA 94041
 Facsimile: (650) 938-5200
	  	$	 25,000.35	  	38,006
			
	 Alsteror Private Life GmbH & Co. KG
 c/o Alpers & Stenger Partnerschaft
 Colonnaden 5
 20354 Hamburg
 Tel.: 49 (0) 40 355336-0
 Fax.: 49 (0) 40 355336-63
	  	$	200,000.15	  	304,044
			
	 Private Life BioMed AG
 c/o Aipers & Stenger Partnerschaft
 Colonnaden 5
 20354 Hamburg
 Tel.: 49 (0) 40 355336-0
 Fax.: 49 (0) 40 355336-63
	  	$	1,000,000.06	  	1,520,219
			
	 Total
	  	$	25,395,005.19	  	38,605,967

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]